TPCN2 Knockout cell line （U-2 OS）

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

The U-2 OS cell line is a foundational human osteosarcoma model established in 1964 by J. Ponten and E. Saksela from a moderately differentiated osteogenic sarcoma of the tibia of a 15-year-old girl. Originally designated as 2T and referenced in image_2f37aa.png, this adherent epithelial-like model is documented to secrete osteosarcoma-derived growth factor (ODGF) and express functional insulin-like growth factor (IGF-1) receptors, insulin-like growth factor-II/Mannose-6-phosphate (IGF-II/M6P) receptors, and IGF-II. Serving as a gold-standard in vitro platform, it is extensively utilized in biomedical research for studying bone oncology pathways, cellular response kinetics, and advanced transfection signaling mechanisms.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.